A case of familial central diabetes insipidus: the response of urinary prostaglandins to 1-deamino-8-D-arginine vasopressin. 1994

Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
Department of Urology, University of Tokyo, Japan.

A case of familial central diabetes insipidus and dilatation of the urinary tract is reported. Administration of desmopressin for 1 year improved urinary tract dilatation with a concomitant reduction in urine volume. Urinary cyclic adenosine monophosphate and prostaglandin E2 excretion increased after treatment.

UI MeSH Term Description Entries
D008297 Male Males
D003894 Deamino Arginine Vasopressin A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. Desmopressin,Vasopressin, Deamino Arginine,1-Deamino-8-D-arginine Vasopressin,1-Desamino-8-arginine Vasopressin,Adiuretin,Adiuretin SD,Apo-Desmopressin,DDAVP,Desmogalen,Desmopressin Acetate,Desmopressin Monoacetate,Desmopressin Monoacetate, Trihydrate,Desmopressine Ferring,Desmospray,Desmotabs,Minirin,Minurin,Nocutil,Octim,Octostim,Acetate, Desmopressin,Arginine Vasopressin, Deamino,Ferring, Desmopressine,Monoacetate, Desmopressin,Monoacetate, Trihydrate Desmopressin,Trihydrate Desmopressin Monoacetate,Vasopressin, 1-Deamino-8-D-arginine,Vasopressin, 1-Desamino-8-arginine
D003919 Diabetes Insipidus A disease that is characterized by frequent urination, excretion of large amounts of dilute URINE, and excessive THIRST. Etiologies of diabetes insipidus include deficiency of antidiuretic hormone (also known as ADH or VASOPRESSIN) secreted by the NEUROHYPOPHYSIS, impaired KIDNEY response to ADH, and impaired hypothalamic regulation of thirst.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006869 Hydronephrosis Abnormal enlargement or swelling of a KIDNEY due to dilation of the KIDNEY CALICES and the KIDNEY PELVIS. It is often associated with obstruction of the URETER or chronic kidney diseases that prevents normal drainage of urine into the URINARY BLADDER. Hydronephroses
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013929 Thromboxane B2 A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). B2, Thromboxane
D014556 Urine Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.
D015121 6-Ketoprostaglandin F1 alpha The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. 6-Keto-PGF1 alpha,6-Oxo-PGF1 alpha,6-Oxoprostaglandin F1 alpha,6 Ketoprostaglandin F1 alpha,6 Keto PGF1 alpha,6 Oxo PGF1 alpha,6 Oxoprostaglandin F1 alpha,F1 alpha, 6-Ketoprostaglandin,F1 alpha, 6-Oxoprostaglandin,alpha, 6-Keto-PGF1,alpha, 6-Ketoprostaglandin F1,alpha, 6-Oxo-PGF1,alpha, 6-Oxoprostaglandin F1

Related Publications

Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
January 1975, Acta medica Academiae Scientiarum Hungaricae,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
March 1980, Orvosi hetilap,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
June 1978, The Journal of pediatrics,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
May 1975, Orvosi hetilap,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
May 1985, Boletin medico del Hospital Infantil de Mexico,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
June 1981, Clinical pharmacology and therapeutics,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
January 1982, International journal of clinical pharmacology, therapy, and toxicology,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
July 1987, Acta endocrinologica,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
January 1994, Haemostasis,
Y Sasaki, and E Higashihara, and T Takeuchi, and K Nutahara, and Y Homma, and Y Aso
March 1974, Endokrinologie,
Copied contents to your clipboard!